Navigation Links
Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
Date:6/16/2009

Uptake of Novel Agents from Novexel, Johnson & Johnson and Wyeth Will Drive Growth, According to a New Report from Decision Resources

WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite generic erosion of key brands, the hospital-acquired gram-negative infections drug market will increase by $1 billion from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Gram Negative Infections finds that the introduction and uptake of next-generation cephalosporins, carbapenems, quinolones, and beta-lactam/beta-lactamase inhibitors, will be a significant driver of market growth through 2018. Among these emerging therapies, Novexel's NXL-104/ceftazidime, a novel beta-lactam/beta-lactamase inhibitor agent, is positioned to offer the most significant advance in the treatment of hospital-acquired gram-negative infections and will earn more than $250 million in sales in 2018. Additionally, the continued uptake of two recent market entrants -- Johnson & Johnson's Doribax and, to a lesser extent, Wyeth's Tygacil -- will also drive the market. Although these three agents and several other emerging therapies will drive market growth, generic erosion of key brands will temper overall market sales through 2018, according to the report.

Generic erosion of top branded products such as piperacillin/tazobactam (Wyeth's Zosyn/Tazocin), imipenem/cilastatin (Merck's Primaxin/Tienam), meropenem (Cubist Pharmaceuticals/AstraZeneca's Merrem/Meronem) and levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit) will have the greatest impact on the market. In 2008, these four products accounted for approximately 50 percent of the hospital-acquired gram-negative infections market. The report forecasts that, in 2018, generic erosion will reduce the combined sales of these agents to approximately 25 percent of the market.

The report also finds that drug development for gram-negative infections has been slow and overshadowed by interest and investment in developing novel therapies for the more lucrative market of hospital-acquired infections due to gram-positive pathogens, namely, methicillin-resistant Staphylococcus aureus (MRSA). However, as competition increases and opportunities decline in the market for hospital-acquired infections due to MRSA, the hospital-acquired gram-negative infections market segment is ripe with attractive drug development opportunities.

"Competition between agents is relatively low in the hospital-acquired gram-negative infections market when compared with the market for hospital-acquired infections due to gram-positive pathogens," said Decision Resources Analyst Hemali Patel, Ph.D. "Minimal competition in the late-stage pipeline and high unmet need will allow novel agents with clearly demonstrated efficacy against key gram-negative pathogens to command a high price and favorable formulary position -- two key attributes that underlie commercial success in this market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Despite overeating, morbidly obese mice gain protection against diabetes
2. Despite grumbling, most Americans say they are happy at work
3. Most patients who have male-to-female sex-change surgery are happy, despite complications
4. Cataract Surgery: A Bargain, Despite the Price
5. UGA study: Youth exposed to smokeless tobacco ads despite settlement
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
8. A Full and Long Life, Despite Diabetes
9. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
10. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
11. Miscarriage myths persist despite prevalence of medical information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has ... go for gold in Rio. Under the care of Maximized Living doctors at ... In an unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial ... for Graduate Medical Education (ACGME) that it has received accreditation for its residency ... of three residency programs that Memorial is currently pursuing, including Pediatrics and Internal ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... ... ... Spine Team Texas, a comprehensive spine physician group specializing in the treatment of ... invited to be a featured speaker at the Texas Society of the American College ... , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, will speak ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 Glycotope GmbH, ... today announces the appointment of Dr. Alfredo Zurlo ... is an oncologist with many years clinical experience and ... industries. His last role was at Mologen AG where ... Executive Board. Previously Dr. Zurlo held various positions at ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
Breaking Medicine Technology: